Research programme: specific androgen receptor modulator/lyase inhibitors - Novus Therapeutics

Drug Profile

Research programme: specific androgen receptor modulator/lyase inhibitors - Novus Therapeutics

Alternative Names: SARM/LI

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Tokai Pharmaceuticals
  • Developer Novus Therapeutics
  • Class
  • Mechanism of Action Androgen receptor antagonists; Lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
  • 10 Nov 2014 Research programme: specific androgen receptor modulator/lyase inhibitors - Tokai is still in preclinical trials for Prostate cancer (castration-resistant ) in USA
  • 10 Jun 2009 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top